Fig. 5: Patient outcome by serum LG2m levels in Cohort 2.

Patient outcome by serum LG2m levels in patients who received a resection and b chemotherapy using gemcitabine and albumin-bound paclitaxel in Cohort 2. Patients with higher serum LG2m level than median level had significantly shorter survivals than those with lower serum LG2m level than median level.